UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2008

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Period from to

Commission file number 012183

BOVIE MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	11-2644611
(State or other jurisdiction Of incorporation or organization)	(IRS Employer Identification No.)

734 Walt Whitman Rd., Melville, New York 11747

(Address of principal executive offices)

(631) 421-5452

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,  a non-accelerated filer or a smaller reporting company. See definitions of “accelerated filer and large accelerated filer” and smaller reporting company  in Rule 12b-2 of the Exchange Act. (check one):

Large Accelerated filer  ¨ Accelerated filer  x Non-accelerated filer  ¨ Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in the Rule 12b-2 of the Exchange Act).    YES ¨ NO x

The number of shares of common stock, par value $0.001 per share, outstanding on October 17, 2008 was 16,224,072.

1

BOVIE MEDICAL CORPORATION
INDEX TO FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2008
Contents		Page
Part I:	Financial Information	3
Item 1:	Consolidated Financial Statements
	Consolidated Balance Sheets –September 30, 2008 and December 31, 2007	3
	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2008 and 2007	5
	Consolidated Statements of Stockholders' Equity for the Year Ended December 31, 2007 and the Nine Months Ended September 30, 2008	6
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2008 and 2007	7
	Notes to Consolidated Financial Statements	8
Item 2:	Management's Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4:	Controls and Procedures	22
Part II.	Other Information	22
Item 1:	Legal Proceedings	22
Item 1A:	Risk Factors	22
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3:	Defaults Upon Senior Securities	22
Item 4:	Submission of Matters to a Vote of Security Holders	22
Item 5:	Other Information	23
Item 6:	Exhibits	23
	Signatures	24

2

PART I. FINANCIAL INFORMATION

ITEM 1: CONSOLIDATED FINANCIAL STATEMENTS

BOVIE MEDICAL CORPORATION
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2008 AND DECEMBER 31, 2007
Assets
	(Unaudited)		(Audited)
	September 30, 2008		December 31, 2007
Current assets:
Cash and cash equivalents	$	4,083,906	$	3,534,759
Trade accounts receivable, net of allowance for doubtful accounts of $8,645 and $8,734, respectively		2,621,092		2,525,451
Inventories		5,443,144		4,521,992
Prepaid expenses		475,983		278,262
Deferred income tax asset, net (Note 1)		219,000		848,223
Total current assets		12,843,125		11,708,687
Property and equipment, net		6,707,603		3,421,455
Other assets:
Brand name/trademark, net		1,509,662		1,509,662
Purchased technology, net		3,532,173		2,102,844
License rights, net		231,454		278,797
Deposits		50,927		44,438
Total other assets		5,324,216		3,935,741
Total Assets	$	24,874,944	$	19,065,883
The accompanying notes are an integral part of the consolidated financial statements.

3

BOVIE MEDICAL CORPORATION
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2008 AND DECEMBER 31, 2007
(CONTINUED)
Liabilities and Stockholders' Equity
	(Unaudited)			(Audited)
	September 30, 2008			December 31, 2007
Current liabilities:
Accounts payable	$	975,151		$	807,437
Accrued payroll		140,436			113,308
Accrued vacation		281,642			229,591
Current portion of due to Lican		50,000			50,000
Customer deposits		168			36,077
Deferred revenue		32,500			56,386
Line of credit  (Note 10)		2,850,000			-
Current income taxes payable		136,053			-
Accrued expenses and other liabilities		875,750			409,880
Total current liabilities		5,341,700			1,702,679
Deferred income taxes payable, net (Note 1)		493,900			408,188
Due to Lican, net of current portion		318,150			318,150
Total liabilities		6,153,750			2,429,017
Contingency  (Note 11)
Stockholders' equity:
Preferred stock, par value $.001; 10,000,000 shares authorized; none issued and outstanding		-			-
Common stock par value $.001; 40,000,000 shares authorized, 16,077,498 and 15,457,088 issued and outstanding on September 30, 2008 and December 31, 2007, respectively		16,078			15,457
Additional paid in capital		22,780,331			22,435,161
Accumulated deficit		(4,020,731	)		(5,813,752	)
Other accumulated comprehensive loss		(54,484	)		-
Total stockholders' equity		18,721,194			16,636,866
Total Liabilities and Stockholders' Equity	$	24,874,944		$	19,065,883
The accompanying notes are an integral part of the consolidated financial statements.

4

BOVIE MEDICAL CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007
(UNAUDITED)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2008			2007			2008			2007
Sales	$	7,295,793		$	7,459,818		$	20,958,672		$	21,602,061
Cost of sales		4,062,424			4,343,709			12,238,925			12,942,901
Gross profit		3,233,369			3,116,109			8,719,747			8,659,160
Other costs and expenses:
Research and development		488,063			415,992			1,430,207			1,232,585
Professional services		344,727			219,354			667,084			609,201
Salaries and related costs		726,761			665,882			2,253,066			2,134,392
Selling, general and administrative		1,061,135			1,104,050			3,221,433			2,990,684
Total costs and expenses		2,620,686			2,405,278			7,571,790			6,966,862
Income from operations		612,683			710,831			1,147,957			1,692,298
Other income (expense), net:
Interest, net		(15,244	)		34,086			15,430			101,323
Gain on cancellation of agreement		-			-			1,495,634			-
Total other income (expense), net		(15,244	)		34,086			1,511,064			101,323
Income before income taxes		597,439			744,917			2,659,021			1,793,621
Benefit (provision) for income taxes		(231,549	)		(273,281	)		(866,000	)		326,192
Net income	$	365,890		$	471,636		$	1,793,021		$	2,119,813
Earnings per share
Basic	$	.02		$	.03		$	.11		$	.14
Diluted	$	.02		$	.03		$	.10		$	.12
Weighted average number of shares outstanding		16,067,979			15,388,073			15,998,150			15,284,033
Weighted average number of shares outstanding adjusted for dilutive securities		17,820,155			17,699,654			17,731,492			17,669,657
The accompanying notes are an integral part of the consolidated financial statements.

5

BOVIE MEDICAL CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2007 AND THE PERIOD
ENDED SEPTEMBER 30, 2008 (UNAUDITED)
													Other
								Additional					Accumulated
	Options			Common				Paid-in		Accumulated			Comprehensive
	Outstanding			Shares		Par Value		Capital		Deficit			Loss			Total
January 1, 2007		3,263,700			15,223,538	$	15,241	$	22,104,399	$	(8,059,343	)	$	--		$	14,060,297
Options granted		137,500			--		--		--		--			--			--
Options exercised, net of stock swaps		(225,300	)		216,121		216		253,684		--			--			253,900
Options forfeited		(42,500	)		--		--		--		--			--			--
Stock based compensation		--			--		--		72,089		--			--			72,089
Other		--			17,429		--		4,989		--			--			4,989
Income for the year		--			--		--		--		2,245,591			--			2,245,591
December 31, 2007		3,133,400			15,457,088		15,457		22,435,161		(5,813,752	)		--			16,636,866
Options exercised, net of stock swaps		(703,150	)		620,410		621		219,779		--			--			220,400
Options granted at market price		197,500			--		--		--		--			--			--
Stock based compensation		--			--		--		125,391		--			--			125,391
Options forfeited		--			--		--		--		--			--			--
Income for the period		--			--		--		--		1,793,021			--			1,793,021
Currency translation adjustment		--			--		--		--		--			(54,484	)		(54,484	)
Comprehensive income		--			--		--		--		--			--			1,738,537
September 30, 2008		2,627,750			16,077,498	$	16,078	$	22,780,331	$	(4,020,731	)	$	(54,484	)	$	18,721,194

The accompanying notes are an integral part of the consolidated financial statements.

6

BOVIE MEDICAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007
(UNAUDITED)
	2008			2007
Cash flows from operating activities:
Net income	$	1,793,021		$	2,119,813
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property and equipment		590,798			492,463
Amortization of intangible assets		120,457			67,739
Provision for (recovery of) inventory obsolescence		(13,401	)		(67,976	)
Loss on disposal of property and equipment		2,692			--
Stock based compensation		125,391			52,693
Non cash re-class adjustment		10,325			(11	)
Provision (benefit) for deferred income taxes		714,934			(371,192	)
Gain on cancellation of agreement		(1,495,634	)		--
Changes in current assets and liabilities:
Receivables		(95,642	)		(164,443	)
Inventories		(907,749	)		(1,003,475	)
Prepaid expenses		(197,720	)		(63,565	)
Deposits		(6,488	)		--
Accounts payable		167,715			(47,082	)
Accrued and other liabilities		545,044			107,605
Current income taxes payable		136,053			-
Customer deposits		(35,909	)		(42,938	)
Deferred revenue		(23,886	)		(106,950	)
Net cash provided by operating activities		1,430,001			972,681
Cash flows from investing activities:
Purchases of property and equipment		(3,850,060	)		(672,200	)
Proceeds from sale of assets		10,573			-
Payments for purchased technology and license rights		(57,283	)		(831,975	)
Net cash used in investing activities		(3,896,770	)		(1,504,175	)
Cash provided by financing activities:
Increase in line of credit		2,850,000			--
Common shares issued		220,400			216,176
Net cash provided in financing activities		3,070,400			216,176
Effect of exchange rate changes on cash and cash equivalents		(54,484	)		--
Net change in cash and cash equivalents		549,147			(315,318	)
Cash and cash equivalents, beginning of period		3,534,759			2,952,892
Cash and cash equivalents, end of period	$	4,083,906		$	2,637,574

Cash paid during the nine months ended September 30, 2008 and 2007:

Interest	$	24,755	$	2,439
Income taxes	$	37,128	$	59,916
Supplemental disclosure of non-cash investing and financing activities - During the nine months ended September 30, 2007, purchased technology increased by $115,000 upon the acquisition of a minority interest in a joint venture.

The accompanying notes are an integral part of the consolidated financial statements

7

BOVIE MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

NOTE 1.  BASIS OF PRESENTATION AND CONSOLIDATION

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, financial position, and cash flows in conformity with accounting principles generally accepted in the U.S.   In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Bovie Medical Corporation and its subsidiaries (collectively, the “Company” or “we”, “us”, “our”) for the periods presented.  Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions management is required to make. Estimates that are critical to the accompanying consolidated financial statements relate principally to the adequacy of our accounts receivable and inventory allowances and the recoverability of long-lived assets.  In addition, stock-based compensation expense represents a significant estimate concerning the future but unknown value of our common stock at some future date based on a formula used in making value determinations.  The markets for the Company’s products are characterized by intense price competition, rapid technological development, evolving standards and short product life cycles, all of which could impact the future realization of its assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that they are determined to be necessary. It is at least reasonably possible that the Company’s estimates could change in the near term with respect to these matters.

For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2007.   Certain prior year amounts may have been reclassified to conform to the presentation used in 2008.

Upon completion of our 2007 tax return and further analysis of our tax credits and net operating loss carryforwards,  the Company became aware that its  income tax provisions and related assets and liabilities were incorrectly reported in its December 13, 2007 10-Q and June 30, 2008 Form 10-Q. This issue has been reviewed by the Company pursuant to SEC Staff Accounting Bulletin No. 99 and determined to be not material to the December 31, 2007 and/or June 30, 2008 financial reports. Pursuant to the SEC Staff Accounting Bulletin No. 108 (“SAB 108”), the Company has corrected its December 31, 2007 consolidated audited balance sheet and  June 30, 2008 financial statements to reflect the corrected amounts. Pursuant to SAB 108, correcting prior period financial statements for immaterial errors would not require previously filed reports to be amended. The following table reflects the adjustments to the financial statements as of December 31, 2007 and as of and for the three and six months ended June 30, 2008 (all amounts in thousands):

Statement of operations	Six Months Ended June 30, 2008
	As Reported		Adjustment			Corrected
Provision for income taxes	$	440	$	200		$	680
Net income	$	1,621	$	( 200	)	$	1,421
Comprehensive income	$	1,574	$	(200	)	$	1,374
Statement of operations	Three Months Ended June 30, 2008
Provision for income taxes	$	320	$	200		$	520
Net income	$	1,430	$	(200	)	$	1,230
Comprehensive income	$	1,383	$	( 200	)	$	1,183

8

Balance sheet	As of June 30, 2008
	As Reported		Adjustment		Corrected
Deferred income tax assets	$	223	$	-	$	223
Total assets	$	21,216	$	-	$	21,216
Income tax liabilities	$	38	$	350	$	388
Total liabilities	$	2,588	$	350	$	2.938
Total liabilities and stockholders’ equity	$	21,216	$	-	$	21,216
Balance sheet	As of December 31, 2007
	As Reported		Adjustment		Corrected
Deferred income tax assets	$	603	$	245	$	848
Total assets	$	18,821	$	245	$	19,066
Income tax liabilities	$	8	$	400	$	408
Total liabilities	$	2,029	$	400	$	2.429
Total liabilities and stockholders’ equity	$	18,821	$	245	$	19,066

NOTE 2.  INVENTORIES

Inventories are stated at the lower of cost or market.  Cost is determined principally on the average cost method.  Inventories at September 30, 2008 and December 31, 2007 were as follows:

	September 30, 2008		December 31, 2007
Raw materials	$	3,175,555	$	2,447,090
Work in process		1,375,764		1,230,172
Finished goods		891,825		844,730
Total	$	5,443,144	$	4,521,992

NOTE 3.  GOODWILL AND INTANGIBLE ASSETS

The Company performs an annual assessment of its goodwill for impairment as of the beginning of the fiscal first quarter. The Company also assesses its goodwill and other intangible assets for impairment when events or circumstances indicate that their carrying value may not be recoverable from future cash flows.

At September 30, 2008 and December 31, 2007 intangible assets consisted of the following:

	September 30, 2008			December 31, 2007
Trade name (life indefinite)	$	1,509,662		$	1,509,662
Purchased technology (9-17 yr life)	$	3,940,618		$	2,438,175
Less:  Accumulated amortization		(408,445	)		(335,331	)
Net carrying amount	$	3,532,173		$	2,102,844
License rights (5 yr life)	$	315,619		$	315,619
Less accumulated amortization		(84,165	)		(36,822	)
Net carrying amount	$	231,454		$	278,797

NOTE 4.  NEW ACCOUNTING PRONOUNCEMENTS

SFAS No. 141 (revised 2007), “Business Combinations” (SFAS No. 141)

In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations” (SFAS No. 141(R)), which replaces SFAS No. 141, “Business Combinations.” SFAS No. 141(R) retains the underlying concepts of SFAS No. 141 in that all business combinations are still required to be accounted for at fair value under the acquisition method of accounting, but SFAS No. 141(R) changes the method of applying the acquisition method in a number of significant aspects. Acquisition costs will generally be expensed as incurred; non-controlling interests will be valued at fair value at the acquisition date; in-process research and development will be recorded at fair value as an indefinite-lived intangible asset at the acquisition date; restructuring costs associated with a business combination will generally be expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date generally will affect income tax expense. SFAS No. 141(R) is effective on a prospective basis for all business combinations for which the acquisition date is on or after the beginning of the first annual period subsequent to December 15, 2008, with an exception related to the accounting for valuation allowances on deferred taxes and acquired contingencies related to acquisitions completed before the effective date. SFAS No. 141(R) amends SFAS No. 109 to require adjustments, made after the effective date of this statement, to valuation allowances for acquired deferred tax assets and income tax positions to be recognized as income tax expense. The impact of our adoption of SFAS 141R will depend upon the nature and terms of business combinations, if any, that we consummate on or after January 1, 2009.

9

SFAS 157 – Fair Value Measurement

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements (“FAS 157”). This standard defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. This standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. In February 2008, the FASB released a FASB Staff Position (FSP FAS 157-2— Effective Date of FASB Statement No. 157) which delays the effective date of SFAS No. 157 for all non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually) to fiscal years beginning after November 15, 2008. The partial adoption of SFAS No. 157 on January 1, 2008, for financial assets and liabilities did not have a material impact on the Company’s consolidated financial position or results of operations.

SFAS 158 – Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statement Nos. 87, 88, 106, and 132(R)

In September 2006, the FASB issued SFAS No. 158, Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statement Nos. 87, 88, 106, and 132(R), or (“FAS 158”). This Statement requires an employer that is a business entity and sponsors one or more single-employer defined benefit plans to (a) recognize the funded status of a benefit plan—measured as the difference between plan assets at fair value (with limited exceptions) and the benefit obligation—in its statement of financial position; (b) recognize, as a component of other comprehensive income, net of tax, the gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost pursuant to FAS 87, Employers’ Accounting for Pensions, or FAS 106, Employers’ Accounting for Postretirement Benefits Other Than Pensions; (c) measure defined benefit plan assets and obligations as of the date of the employer’s fiscal year-end statement of financial position (with limited exceptions); and (d) disclose in the notes to financial statements additional information about certain effects on net periodic benefit cost for the next fiscal year that arise from delayed recognition of the gains or losses, prior service costs or credits, and transition assets or obligations.  An employer with publicly traded equity securities is required to initially recognize the funded status of a defined benefit postretirement plan and to provide the required disclosures as of the end of the fiscal year ending after December 15, 2006. Adoption of this statement did not have a material effect on the Company’s consolidated financial position or results of operations.

SFAS 159 – The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an amendment of FASB Statement No. 115," which provides a fair value option election that permits entities to irrevocably elect to measure certain financial assets and liabilities (exceptions are specifically identified in the Statement) at fair value as the initial and subsequent measurement attribute, with changes in fair value recognized in earnings as they occur. SFAS No. 159 permits the fair value option election on an instrument-by-instrument basis at initial recognition of an asset or liability or upon an event that gives rise to a new basis of accounting for that instrument.  The adoption of SFAS No. 159 on January 1, 2008, for financial assets and liabilities did not have a material impact on the Company’s consolidated financial position or results of operations.

10

SFAS No. 160 - Non-controlling Interests in Consolidated Financial Statements, an amendment of ARB No. 51

In December 2007, the FASB issued SFAS No. 160, “Non-controlling Interests in Consolidated Financial Statements, an amendment of ARB No. 51” (“SFAS No. 160"). SFAS No. 160 will change the accounting and reporting for minority interests, which will be recharacterized as non-controlling interests (NCI) and classified as a component of equity. This new consolidation method will significantly change the accounting for partial and/or step acquisitions. SFAS No. 160 will be effective for the Company in the first quarter of fiscal year 2010. The Company is currently evaluating the impact that the adoption of SFAS No. 160 will have, but does not believe it will be material to the consolidated financial statements.

SFAS 161 – Disclosures about Derivative Instruments and Hedging Activities — an amendment of FASB Statement No. 133

In March 2008, the FASB issued Statement of Financial Accounting Standards No. 161, Disclosures about Derivative Instruments and Hedging Activities — an amendment of FASB Statement No. 133 (“FAS 161”). This Standard requires enhanced disclosures regarding derivatives and hedging activities, including: (a) the manner in which an entity uses derivative instruments; (b) the manner in which derivative instruments and related hedged items are accounted for under Statement of Financial Accounting Standards No. 133, Accounting for Derivative Instruments and Hedging Activities; and (c) the effect of derivative instruments and related hedged items on an entity’s financial position, financial performance, and cash flows. The Standard is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. As FAS 161 relates specifically to disclosures, the Standard will have no impact on our consolidated financial position or results of operations.

EITF Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services Received to Be Used in Future Research and Development Activities” (EITF No. 07-3)

In June 2007, the Emerging Issues Task Force (EITF) reached a consensus on EITF Issue No. 07-3, “Accounting for Nonrefundable Advance Payments for Goods or Services Received to Be Used in Future Research and Development Activities” (EITF No. 07-3). EITF No. 07-3 requires companies that are involved in research and development activities to defer nonrefundable advance payments for future research and development activities and to recognize those payments as goods and services are delivered. The Company will be required to assess on an ongoing basis whether or not the goods or services will be delivered and to expense the nonrefundable advance payments immediately if it is determined that delivery is unlikely. EITF No. 07-3 is effective for new arrangements entered into subsequent to the beginning of the Company’s fiscal year 2009. The Company is currently evaluating the impact that the adoption of EITF No. 07-3 will have, but does not believe it will be material to the consolidated financial position or results of operations.

FASB Staff Position (“FSP”) FSP FAS 142-3, Determination of the Useful Life of Intangible Assets or FSP FAS 142-3.

In April 2008, the FASB issued FSP FAS 142-3, Determination of the Useful Life of Intangible Assets or FSP FAS 142-3. FSP FAS 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142, Goodwill and Other Intangible Assets. The intent of the position is to improve the consistency between the useful life of a recognized intangible asset under SFAS No. 142 and the period of expected cash flows used to measure the fair value of the intangible asset. FSP FAS 142-3 is effective for fiscal years beginning after December 15, 2008. The Company is currently evaluating the impact that the adoption of FSP FAS 142-3 will have, but does not believe it will be material to the consolidated financial position or results of operations.

SFAS No. 162 -  The Hierarchy of Generally Accepted Accounting Principles

In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally Accepted Accounting Principles or SFAS No. 162. SFAS No. 162 identifies the sources of accounting principles and the framework for selecting the principles used in the preparation of financial statements of nongovernmental entities that are presented in conformity with GAAP. This statement shall be effective 60 days following the Securities and Exchange Commission’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles. The Company does not believe that implementation of this standard will have a material impact on its consolidated financial position, results of operations or cash flows.

11

FASB Staff Position (“FSP”) Accounting Principles Board (“APB”) 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)

In May 2008, the FASB issued FASB Staff Position (“FSP”) Accounting Principles Board (“APB”) 14-1, “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement).” FSP APB 14-1 applies to convertible debt instruments that, by their stated terms, may be settled in cash (or other assets) upon conversion, including partial cash settlement of the conversion option. FSP APB 14-1 requires bifurcation of the instrument into a debt component that is initially recorded at fair value and an equity component. The difference between the fair value of the debt component and the initial proceeds from issuance of the instrument is recorded as a component of equity. The liability component of the debt instrument is accreted to par using the effective yield method; accretion is reported as a component of interest expense. The equity component is not subsequently re-valued as long as it continues to qualify for equity treatment. FSP APB 14-1 must be applied retrospectively to previously issued cash-settleable convertible instruments as well as prospectively to newly issued instruments. FSP APB 14-1 is effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. We are currently evaluating the impact of FSP APB 14-1 to our consolidated financial statements.

FASB Staff Position (“FSP”) No. EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities

In June 2008, the FASB issued FASB Staff Position (“FSP”) No. EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities. This FASB Staff Position (FSP) addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and, therefore, need to be included in the earnings allocation in computing earnings per share (EPS) under the two-class method described in paragraphs 60 and 61 of FASB Statement No. 128, Earnings per Share. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of EPS pursuant to the two-class method. At this time, the Company does not believe FSP EITF 03-6-1 will have any impact on our earnings per share calculations.

NOTE 5.  STOCKHOLDERS’ EQUITY

During the nine month period ended September 30, 2008, we issued 620,410 common shares on the exercise of employee and non-employee options.  As consideration for such issuances, we received 82,740 common shares in stock swaps and cash of $220,400.

NOTE 6.  EARNINGS PER SHARE

We compute basic earnings per share (“basic EPS”) by dividing net income by the weighted average number of common shares outstanding for the reporting period.  Diluted earnings per share (“Diluted EPS”) gives effect to all potential dilutive shares outstanding (in our case, employee stock options) during the period.  There were 1,733,342 and 2,385,624 potentially dilutive shares outstanding during the nine month periods ended September 30, 2008 and 2007, respectively. The shares used in the calculation of Diluted EPS exclude options to purchase shares where the exercise price was greater than the market close price on September 30, 2008.  Such shares aggregated 355,000 and 130,000 during the nine months ended September 30, 2008 and 2007, respectively.

NOTE 7.  FOREIGN CURRENCY TRANSLATION

The United States dollar is the functional currency of the Company’s operations in the United States and in line with determining guidance outlined in FASB 52, has also been determined to be the functional currency for the Company’s Canadian subsidiary. FASB 52 provides for using the remeasurement method in translating the foreign subsidiary’s financial statements into U.S. dollars.  Monetary assets and liabilities denominated in foreign currency are translated at the current rate, while nonmonetary assets, liabilities, and shareholder equity accounts are translated  at the appropriate historical rate. Revenue and expenses are translated at the weighted-average exchange rate for the period. The calculated remeasurement gain or loss adjustment is then recorded as either other accumulated comprehensive income or loss in the shareholders’ equity section of the balance sheet.

12

NOTE 8.  STOCK-BASED COMPENSATION

Under the Company’s stock option plan, options to purchase Common Shares may be granted to key employees, officers and directors of the Company by the Board of Directors. The Company accounts for stock options in accordance with SFAS Statement 123 (R) with option expense amortized over the vesting period based on the binomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense. During the nine months ended September 30, 2008 the Company recorded stock based compensation  of approximately $125,400.

The Company valued these stock option grants using the binomial lattice valuation model with the following assumptions:

	Three Months Ended September 30, 2008			Three Months Ended September 30, 2007
Expected volatility		30	%		26	%
Expected dividend yield		0.00	%		0.00	%
Expected term (in years)		5 - 7			5 - 7
Risk-free rate		2.7	%		5.0%–5.5	%

Due to the lack of sufficient historical trading information with respect to its own shares, the Company estimates expected volatility based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The expected dividend yield is zero based on historical data.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term is based on an analysis of the options term and the exercise behavior of employees.

A summary of stock-based award activities during the nine months ended September 30, 2008 is presented below:

	Stock Options
Outstanding at January 1, 2008		3,133,400
Granted at market price		197,500
Exercised		(703,150	)
Forfeited/expired		--
Outstanding at September 30, 2008		2,627,750

NOTE 9.  INCOME TAXES

During the nine months ended September 30, 2008,we used our remaining net operating loss carryforwards and research and development tax credits, and took advantage of certain accelerated depreciation deductions,  to substantially offset current income taxes that would otherwise be due.     Assuming we do not incur operating losses in the future, we anticipate that we will provide for current income taxes at rates that approximate statutory rates commencing with the quarter ended December 31, 2008.

NOTE 10.  SIGNIFICANT CURRENT QUARTER EVENTS

In June 2008, we committed ourselves to purchase a new facility in Largo, Florida for $3,000,000.  We made the decision to relocate in order to consolidate our operations under one roof and for additional manufacturing space needed to accommodate the anticipated new product lines currently under development as they near completion, and accordingly we anticipate selling our facility located at 7100 30th Avenue N., St. Petersburg, FL when we move to our new headquarters.

We acquired our new facility on September 11, 2008 and used borrowings under our line of credit to fund a substantial portion of the purchase price. The line of credit allows for maximum borrowings of $5,000,000, and advances under such line bear interest at 4.39% and are secured by a perfected first security interest in all business assets, namely inventory, accounts receivable, equipment, and general intangibles.   For the first nine months the full amount of the line is available, and subsequent to such time, available borrowings will be based on a borrowing base utilizing a percentage of eligible receivables and inventories. We anticipate that the balance of this line existing at September 30, 2008 will be paid when we secure permanent financing (we expect this financing will  result from a $4,000,000 Industrial Revenue Bond that we anticipate closing  in November 2008).  Upon the closing of such financing, our working capital position will increase significantly as substantially all of the liability will be shifted from current to non-current liabilities.

13

The lease on the other facility that we currently occupy expires on October 31, 2013.  Upon our relocation to our new facility (which we anticipate will occur in the second quarter of 2009), we will be required to record an expense and liability for the lesser of a lease termination fee we hope to negotiate, or the fair value of the net remaining lease rentals (i.e. the present value of future minimum lease payments of approximately $780,000 due under the lease minus estimated sublease rentals we reasonably can expect to receive).

NOTE 11.  CONTINGENCY

A civil action has been instituted by Erbe USA, Inc. (“Erbe”) in the US District Court for the Northern District of Georgia, Atlanta Division, against Bovie and a recently hired employee, seeking equitable relief and unspecified damages.  The complaint essentially alleges that the newly hired employee, among other things, breached his employment agreement with Erbe USA, Inc., (“Erbe”) by wrongfully taking Erbe’s confidential information and trade secrets for use in his new employment with the assistance of Bovie.  Bovie denies the allegations and pursuant to a Consent and Protective Order, the action has been stayed pending mutual discovery by the parties.  It is too early in the proceeding to determine the extent, if any, of Bovie’s possible exposure in the lawsuit.  As such, no effect has been given herein to any loss that may result from the resolution of this matter in the accompanying consolidated financial statements.

NOTE 12. – GEOGRAPHIC AND SEGMENT INFORMATION

The Company has two reportable business segments, including Bovie Medical Corporation (located in the United States) and Bovie Canada, (located in Windsor, Canada). Since Bovie Canada operations resulted in a loss greater than 10% of our consolidated net income (on an absolute value basis) we are required to report certain information broken out by segment for the periods in the table listed below.

For the three months ended September 30: (in thousands)

	USA		Canada			USA		Canada
	2008		2008			2007		2007
Sales, net	$	7,071	$	225		$	7,325	$	134
Gross profit		3,166		67			3,175		(59	)
Operating expenses		2,346		275			2,228		177
Net income (loss)	$	574	$	(208	)	$	708	$	(236	)

For the nine months ended September 30: (in thousands)

	USA		Canada			USA		Canada
	2008		2008			2007		2007
Sales, net	$	20,551	$	408		$	21,391	$	211
Gross profit		8,746		(26	)		8,826		(167	)
Operating expenses		6,812		760			6,634		338
Net income (loss)	$	2,579	$	(786	)	$	2,625	$	(505	)

NOTE 13 - RELATED PARTY TRANSACTION

During the quarter ended September 30, 2008, we paid consulting fees of approximately $28,400 to an entity owned by one of our directors.

End of financial statements

14

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Executive Level Overview

We are a medical device company engaged in the manufacturing and marketing of electrosurgical devices. Our medical products include a wide range of devices including electrosurgical generators and accessories, cauteries, medical lighting, nerve locators and other products.

We internally divide our operations into three product lines.  Electrosurgical products, battery operated cauteries and other products. The electrosurgical segment sells electrosurgical products which include dessicators, generators, electrodes, electrosurgical pencils and various ancillary disposable products. These products are used in surgery for the cutting and coagulation of tissue. Battery operated cauteries are used for precise hemostasis (to stop bleeding) in ophthalmology and in other fields. Our other revenues are derived from nerve locators, disposable and reusable penlights, medical lighting, license fees, development fees and other miscellaneous income.

Domestic sales accounted for approximately 83% of total revenues in the first nine months of 2008 as compared to approximately 85% in the first nine months of 2007.  Most of the Company’s products are marketed through medical distributors, which distribute to more than 6,000 hospitals, as well as doctors and other health-care facilities. The Company’s products are sold in more than 150 countries through local distributors coordinated by our in-house sales and marketing personnel at the St. Petersburg, Florida facility. We have no manufacturing facilities or branch offices other than the Florida and Canadian facilities.

Our ten largest customers accounted for approximately 69% and 71% of net revenues for the first nine months of 2008 and 2007 respectively.  At September 30, 2008 and 2007, our ten largest trade receivables accounted for approximately 67% and 67% of our net receivables, respectively.  In the first nine months of 2008 and 2007 one customer accounted for 19% and 21% of total sales, respectively.

Our business is generally not seasonal in nature.

Outlook

The Company’s outlook for the remainder of fiscal 2008, ending December 31, continues to be optimistic regarding the further development of new proprietary products.  We will continue to direct our resources and effort in this area; thus, positioning the Company to be less dependent on OEM business which is marked by lower margins and unpredictable growth.

Subsequent to the close of our third quarter the following milestones were reported:

§   CE Mark for our SEER tissue resection device intended for initial use in liver oncology.  The CE Mark allows for the sale of the device in the European Union and all countries recognizing the mark.

§   We filed a 510(k) pre-notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for the SEER.

§   We received a 510(k) clearance from the FDA to market our ICON GP generator to be used in general surgery and in conjunction with our Polarian vessel sealing instruments.  As of October 31, 2008 a 510(k) application has not been filed for Polarian vessel sealing instruments.

Disclaimer

We believe these milestones hold the potential to increase both sales and margins.  However, unanticipated issues, should they arise, may delay or even terminate a product’s development and contribution to overall revenues.

The outlook is based on a number of assumptions, which are subject to change; some of which are outside our control.  A variation in our assumptions may result in a change in this outlook.

Result of Operations (to be read in conjunction with the consolidated statements of operations)

The table below outlines the components of the consolidated statements of operations as a percentage of net sales and the year-to-year percentage change in dollar amounts for the quarters ended September 30, 2008 and 2007:

15

							Percentage Change in Dollar Amounts								Percentage Change in Dollar Amounts
	3rd Quarter									Nine months
	2008			2007						2008			2007
	%			%			%			%			%		%
Sales		100.0			100.0			(2.2	)		100.0			100.0		(3.0	)
Cost of sales		55.7			58.2			(6.5	)		58.4			59.9		(5.4	)
Gross profit		44.3			41.8			3.8			41.6			40.1		0.7
Other costs:
Research & development		6.7			5.6			17.3			6.8			5.7		16.0
Professional services		4.7			3.0			57.2			3.2			2.8		9.5
Salaries and related costs		10.0			8.9			9.1			10.8			9.9		5.6
Selling, general and administrative		14.5			14.8			(3.9	)		15.4			13.9		7.7
Total other costs		35.9			32.3			9.0			36.1			32.3		8.7
Income from operations		8.4			9.5			(13.8	)		5.5			7.8		(32.2	)
Interest income, net		(0.2	)		0.5			(144.7	)		0.1			0.5		(84.8	)
Other Income		0.0			0.0			0.0			7.1			0.0		100.0
Income before income tax		8.2			10.0			(19.8	)		12.7			8.3		48.2
Benefit (provision) for income taxes		(3.2	)		(3.7	)		(15.3	)		(4.1	)		1.5		(365.6	)
Net income		5.0			6.3			(22.4	)		8.6			9.8		(15.4	)

Results of Operations – Nine months ended September 30, 2008 compared to nine months ended September 30, 2007

The table below sets forth domestic/international and product line sales information for the first nine months of 2008 and 2007:

					%age change			Increase/
	2008		2007		2008/2007			(Decrease)
Net Sales (in thousands):
Domestic	$	17,294	$	18,409		(6.1	)	$	(1,115	)
International		3,665		3,193		14.8			472
Total net sales	$	20,959	$	21,602		(3.0	)	$	(643	)
Product line sales:
Electrosurgical	$	14,480	$	15,182		(4.6	)	$	(702	)
Cauteries		4,673		4,607		1.4			66
Other		1,806		1,813		(0.4	)		(7	)
Total net sales	$	20,959	$	21,602		(3.0	)	$	(643	)

The results of operations for the nine months ended September 30, 2008 show a decrease in sales as compared to the first nine months of 2007. Sales of electrosurgical products decreased by 4.6% or approximately $1.1 million compared to the same nine month period of 2007 while sales of cauteries increased by 1.4% from $4.6 million to $4.7 million. Other sales remained approximately the same. No sales of one particular electrosurgical product dominated the number of units sold.

16

Arthrex sales of generators and accessories decreased by approximately $600,000 or 13.4% to $4.0 million for the nine months ended September 30, 2008 from $4.6 million for the nine months ended September 30, 2007.

Domestic sales were $17.3 million for nine months ended September 30, 2008, representing a decrease of 6.1% from the same period last year.  The decrease was the mainly the result of lower OEM generator sales. International sales were $3.7 million for the nine months ended September 30, 2008, representing an increase of 14.8% over the same period in 2007.

Cost of sales represented 58.4% of sales during the nine months ended September 30, 2008 as compared to 59.9% of sales during the same period in 2007, a total of $12.2 million and $12.9 million, respectively, a decrease of $0.7 million. The net decrease in cost of sales is the result of an 8.9% decrease in direct material costs plus a 1.2% decrease in direct labor costs, offset by a 5.8% increase in manufactured overhead. Manufactured overhead increased in the first nine months of 2008 by approximately $63,000 over the same nine month period in 2007 mainly due to increases in freight costs, depreciation expense, and tooling costs associated with the production of new product lines.

Research and development expenses were 6.8% and 5.7% of sales for the nine months ended September 30, 2008 and 2007, respectively.  These expenses increased 16.0% (or approximately $200,000) in 2008 over the corresponding period in 2007. This increase is largely due to costs related to our Canadian facility preparing to launch the modular forceps instrument (MEG), as well as continued development of our Polarian vessel sealing technology.  We received our CE mark for the MEG and commenced production and sales in June 2008. We also filed for and received 510K clearance to market the MEG on July 24, 2008. In addition, in June of 2008 we started production and sales of our new plasma probe.

Professional services increased from approximately $609,000 in the first nine months of 2007 to approximately $667,000 in the first nine months of 2008, an increase of approximately $58,000 or 9.5%.  This net increase is the result of increased legal costs from the Erbe lawsuit offset partially by a reduction in legal costs related both to manufacturing and development contracts and patent related filings for the nine months ended September 30, 2008 compared to the same period in 2007.

Salaries and related costs increased in the first nine months of 2008 by 5.6% to $2.25 million as compared to the first nine months of 2007 of $2.1 million.  The increase was mainly attributable to additional employees needed to foster our growth in various areas coupled with annual salary increases.

Selling, general and administrative expenses increased in the first nine months of 2008 by 7.7% to $3.2 million as compared to the first nine months of 2007 of $3.0 million.  This was mainly attributable to increased costs related to establishing a sales and distribution channel in Europe to distribute our MEG instruments and other future devices, sales commissions, increases in insurance and regulatory costs, and an increase in amortization for intellectual property recently placed in production.

We have agreements with various sales representatives to develop markets for our new products and to maintain customer relations.  Our current representatives receive an average commission of approximately 4% of sales in their market areas.  In the first nine months of 2008 and 2007, commissions expense  approximated $560,000 and $463,000 respectively, an increase of 21.0%.  The increase in sales commissions was a result of a difference in product mix which resulted in more commission based sales in 2008 than in 2007..

Net interest earned decreased by approximately $86,000 during the first nine months of 2008 when compared to the same period in 2007 primarily as a result of our invested cash balances yielding lower interest rates, and interest paid on the line of credit. The line of credit was used as a bridge loan to purchase the new facility (see Note 10).

For the nine months ended September 30, 2008 we realized other income in the amount of approximately $1.5 million. The increase was the result of our acquiring intellectual property from a contract settlement with Boston Scientific Corporation.

Our income tax provision for the nine months ended September 30, 2008 was approximately $866 as compared to a net tax benefit of approximately $326 during the nine months ended September 30, 2007.  The significant benefit in 2007 resulted from the reversal of a valuation allowance that had reduced our net deferred income tax asset at December 31, 2006.  Our effective tax rate was approximately 33% for the first nine months of 2008, which percentage is somewhat less than statutory rates because of the utilization of certain research and development tax credits we used during such period. .

17

Results of Operations - Three months ended September 30, 2008 compared to three months ended September 30, 2007

The table below sets forth domestic/international and product line sales information for the third quarter of 2008 and 2007:

					%age change			Increase/
	2008		2007		2008/2007			(Decrease)
Net Sales (in thousands)
Domestic	$	6,348	$	6,373		(0.3	)	$	(25	)
International		948		1,087		(12.8	)		(139	)
Total net sales	$	7,296	$	7,460		(2.2	)	$	(164	)
Product line sales:
Electrosurgical	$	5,139	$	5,328		(3.6	)	$	(189	)
Cauteries		1,532		1,557		(1.6	)		(25	)
Other		625		575		8.7			50
Total net sales	$	7,296	$	7,460		(2.2	)	$	(164	)

Sales for the three month period ended September 30, 2008 were approximately $7.3 million as compared to $7.5 million for the same period in 2007, a slight decrease of $0.2 million or 2.2%.  The decrease was mainly attributed to lower international sales.

Cost of goods sold decreased from $4.3 million to $4.0 million a decrease of $0.3 million or 6.5% for the three month period ended September 30, 2008 as compared to the same period in 2007.

Gross profit, as a dollar amount, increased $0.1 million or 3.8% from $3.1 million in the third quarter 2007 to $3.2 million for the third quarter 2008.  The gross profit as a percentage of sales increased from 41.8% in 2007 to 44.3% in 2008.  The reason for the increase was mainly attributed to sales product mix.  We had an increase in sales of higher margin products as opposed to OEM sales which have a lower gross margin.

Research and development increased by approximately $72,000, or 17.3% from $416,000 to $488,000 for the quarters ended September 30, 2007 and September 30, 2008, respectively.  The increase was attributable to costs for new products under development as they approach completion (i.e. Polarian, GP Icon, and SEER device).

Professional fees increased by approximately $125,000 or 57.2% from $219,354 to $345,000 for the quarters ended September 30, 2007 to September 30, 2008, respectively. This increase was mainly attributed to increased legal costs for the Erbe lawsuit.

Salaries and related costs increased from approximately $666,000 to $727,000 for the quarters ended September 30, 2007 to September 30, 2008, respectively, an increase of approximately $61,000 or 9.1%. This increase was mainly attributable to the addition of two new management positions to develop and foster sales growth in the plasma probe, ICON GI, and SEER device product lines, as well annual salary increases.

Selling, general and administrative expenses decreased by approximately $43,000 or 3.9% from $1,104,000 to $1,061,000 for the quarters ended September 30, 2007 to September 30, 2008, respectively.

For the quarter ended September 30, 2008 we had a net interest expense in the amount of $15,244 compared to a net  interest income of $34,086 for the same quarter ended September 30, 2007. This represents a decrease of approximately $49,300 or 144.7%., and is a direct result from the investment of our cash balances yielding lower interest rates coupled with an increase of interest expense on our line of credit.

As a result of the above, income before income taxes for the three months ended September 30, 2008 was $597,439 compared to $744,917  for the same three months period in 2007.

Our income tax provision for the three months ended September 30, 2008 was approximately $232,000 as compared to approximately $273,000 during the nine months ended September 30, 2007. Our effective tax rate approximated statutory rates of approximately 39% for the quarter.

18

Marketing and Sales

We sell our products through distributors both overseas and in U.S. markets.  New distributors are contacted through responses to our advertising in domestic and international medical journals and domestic or international trade shows.

An adequate supply of raw materials is available from both domestic and international suppliers.  The relationship between us and our suppliers is generally limited to individual purchase order agreements, supplemented by contractual arrangements with key vendors to ensure availability of certain products.  We have developed multiple sources of supply where possible.

Product Development

Most of the Company’s products and product improvements have been developed internally. Funds for this development have resulted primarily from internal cash flow and the issuance of common stock upon the exercise of stock options. The Company maintains close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and development. New and improved products play a critical role in the Company’s sales growth. The Company continues to place emphasis on the development of proprietary products and product improvements to complement and expand its existing product lines. The Company has a centralized research and development focus, with its Florida and Canadian manufacturing locations responsible for new product development and product improvements. Our research, development and engineering units at the manufacturing location maintain relationships with distribution locations and customers in order to provide an understanding of changes in the market and product needs. During 2007 and into 2008 we invested in the ICON GS (J-Plasma technology), modular laparoscopic and Endoscopic instruments, and the Gastrointestinal “GI” device and undertook development of Cardio and Urological Electrosurgical devices for a contractual partner. The ongoing cost for this development will be paid from operating cash flows.

In the next year we do not contemplate any material purchase or acquisition of assets that our ordinary cash flow and or credit line would be unable to sustain.

Reliance on Collaborative, Manufacturing and Selling Arrangements

We are dependent on certain contractual OEM customers for product development, wherein we are to provide the manufacturing of the product developed. However, the customer has no legal obligation to purchase the developed products. Should the collaborative customer fail to give us purchase orders for the product after development, our future business and value of related assets could be negatively affected. Furthermore, no assurance can be given that a collaborative customer may give sufficient high priority to our products. In addition, disagreements or disputes may arise between Bovie and its contractual customers, which could adversely affect production of our products. We also have informal collaborative arrangements with two foreign suppliers where in we request the development of certain items and components and we purchase them pursuant to purchase orders. Our purchase orders are never more than one year and are supported by orders from our customers.

Liquidity and Capital Resources

Our working capital at September 30, 2008 approximated $7.5 million as compared to working capital of approximately $9.8 million at September 30, 2007.  The decline in working capital resulted from our decision to utilize our line of credit to temporarily fund the purchase of our new facility (see Note 10), and we anticipate that such reduction will be eliminated when we close on permanent financing for such facility. Accounts receivable day sales outstanding were 37.0 days and 42.6 days at September 30, 2008 and 2007 respectively.

We generated cash from operations of approximately $1.4 million and $1.0 million for the nine months ended September 30, 2008 and 2007 respectively.

In the first nine months ended September 30, 2008 we used approximately $3.9 million for the purchase of property and equipment, and used approximately $57,000 on legal and other fees to acquire purchased technology.

Our investing activities were primarily funded by borrowings under our line of credit as discussed in the first paragraph above.

We had approximately $4.1 million in cash and cash equivalents at September 30, 2008. We believe our cash on hand, as well as anticipated cash flows from operations, and the proceeds from an industrial revenue bond of approximately $4,000,000, will be sufficient to fund future operating capital requirements, future manufacturing facility construction, and other capital expenditures and future acquisitions to supplement our current product offerings. Should additional funds be required, subject to completion of our industrial revenue bonds financing, the Company will again have $5.0 million of borrowing capacity available under our line of credit from RBC Centura Bank (assuming we pay the balance of the line of credit when we close on our permanent financing for our new facility).

19

At September 30, 2008, the Company has non-cancelable purchase commitments of approximately $3.8 million.  In addition, the Company’s future contractual obligations for agreements with initial terms greater than one year, are summarized as follows (in thousands):

	Years ended December 31,
	2009		2010		2011		2012		Thereafter
Operating leases		208		199		172		167		143
Employment Agreements		1,022		799		858		72		-

Our future results of operations and the other forward-looking statements contained herein, particularly the statements regarding growth in the medical products industry, capital spending, research and development, and marketing and general and administrative expenses, involve a number of risks and uncertainties. In addition to the factors discussed above, there are other factors that could cause actual results to differ materially, such as business conditions and the general economy, competitive factors including rival manufacturers’ availability of components at reasonable prices, risk of nonpayment of accounts receivable, risks associated with foreign operations and litigation involving intellectual property and consumer issues.

Critical Accounting Estimates

We have adopted various accounting policies to prepare the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements.

The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

Allowance for Doubtful Accounts

We maintain an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. We make estimates regarding the future ability of our customers to make required payments based on historical credit experience and expected future trends. If actual customer financial conditions are less favorable than projected by management, additional accounts receivable write-offs may be necessary, which could unfavorably affect future operating results.

Inventory Reserves

We maintain reserves for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience, and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which could unfavorably affect future operating results.

20

Impairment of Goodwill and Other Long-Lived Assets

We review long-lived assets which are held and used, including property and equipment and purchased intangible assets, for impairment whenever changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Such evaluations compare the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset over its expected useful life and are significantly impacted by estimates of future prices and volumes for our products, capital needs, economic trends and other factors which are inherently difficult to forecast. If the asset is considered to be impaired, we record an impairment charge equal to the amount by which the carrying value of the asset exceeds its fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique.

We test our goodwill for impairment, at a minimum, annually.   The goodwill impairment test is a two-step process. The first step of the impairment analysis compares the fair value of the goodwill to its carrying amount. In determining fair value, the accounting guidance allows for the use of several valuation methodologies, although it states quoted market prices are the best evidence of fair value. If the fair value is less than the assets’ carrying amount, we recognize an impairment loss equal to that excess amount.

Income Taxes

We operate in multiple tax jurisdictions both inside and outside the United States. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions. Tax audits associated with the allocation of this income and other complex issues may require an extended period of time to resolve and may result in income tax adjustments if changes to the income allocation are required between jurisdictions with different tax rates. Because tax adjustments in certain jurisdictions can be significant, we record accruals representing our best estimate of the probable resolution of these matters. To the extent additional information becomes available, such accruals are adjusted to reflect the revised estimated probable outcome.

Other Matters

We distribute our products throughout the world. As a result, our financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Our operating results are primarily exposed to changes in exchange rates among the United States dollar and European currencies, in particular the euro and the British pound. When the United States dollar weakens against foreign currencies, the dollar value of sales denominated in foreign currencies increases. When the United States dollar strengthens, the opposite situation occurs. We manufacture our products in the United States, China, Canada and Bulgaria and incur the costs to manufacture in US dollars. This worldwide deployment of factories serves to partially mitigate the impact of the high costs of manufacturing in the US.

ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk

Interest rate risk

Our financial instruments include cash, cash equivalents and short-term investments. We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid overnight money market investments. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term overnight securities. If a 10% change in interest rates were to have occurred on September 30, 2008, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.

Foreign Currency Risk

We operate internationally and enter into transactions denominated in foreign currencies. As such, our financial results are subject to the variability that arises from exchange rate movements in relation to the U.S. dollar. Our foreign currency exposures are minimal and are not a material financial risk and are currently limited to the Canadian dollar and the Euro. We recorded a $54,484 loss to accumulated other comprehensive loss for the first nine months of 2008 as a result of changes in the relationship of the U.S. to the Canadian dollar using the remeasurement method of translating the Canadian subsidiary’s financial statements into U.S. dollars. Other foreign currency losses amounted to $2,692.

21

To date, we have not hedged our exposure to changes in foreign currency exchange rates, and as a result, we are subject to foreign currency transaction and translation gains and losses. We purchase goods and services in U.S. and Canadian dollars and have recently begun to invoice certain product sales in Euros. Foreign exchange risk is managed primarily by satisfying foreign denominated expenditures with cash flows or assets denominated in the same currency.

ITEM 4.  CONTROLS AND PROCEDURES

(a)  Evaluation of disclosure controls and procedures

An evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures [as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)] as of September 30, 2008 was carried out under the supervision and with the participation of the Company’s management, including the President and Chief Executive Officer and the Chief Financial Officer (“the Certifying Officers”).  Based on that evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.

Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act is accumulated and communicated to management, including our President and Chief Financial Officer, as appropriate, to allow timely decisions and timely reporting regarding required disclosure.

(b)  Changes in internal controls

There were no changes to the Company’s internal control over financial reporting during the quarter ended September 30, 2008 that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II.  OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

A civil action has been instituted by Erbe USA, Inc. (“Erbe”) in the US District Court for the Northern District of Georgia, Atlanta Division, against Bovie and a recently hired employee, seeking equitable relief and damages.  The complaint essentially alleges that the newly hired employee, among other things, breached his employment agreement with Erbe USA, Inc., (“Erbe”) by wrongfully taking Erbe’s confidential information and trade secrets for use in his new employment with the assistance of Bovie.  Bovie denies the allegations and pursuant to a Consent and Protective Order, the action has been stayed pending mutual discovery by the parties.  It is too early in the proceeding to determine the extent, if any, of Bovie’s possible exposure in the lawsuit.

ITEM 1A.  RISK FACTORS

There have been no material changes to the Risk Factors previously disclosed in our Form 10K for the year ended December 31, 2007, in response to Item 1A to Part 1 of Form 10K.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

22

ITEM 5.  OTHER INFORMATION

(a)   Since our last proxy statement disseminated to our shareholders in connection with our last annual meeting of shareholders held on November 6, 2008, there have been no changes in the procedures by which our security holders or 5% holders may recommend nominees to our Board of Directors.

(b)   The Company has received 510-K clearance to market its ICON GP/VS generator. This product is designed to add safety features and improve convenience in performing general purpose procedures, and includes a blood vessel sealing component.

ITEM 6.  EXHIBITS

31.1	Certifications of Andrew Makrides, President and Chief Executive Officer of Registrant pursuant to Rule 13a-14 adopted under the Securities Exchange Act of 1934, as amended, and Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certifications of Gary D. Pickett, Chief Financial Officer of Registrant pursuant to Rule 13a-14 adopted under the Securities Exchange Act of 1934, as amended, and Section 302 of the Sarbanes-Oxley act of 2002.
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

23

SIGNATURES:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bovie Medical Corporation.

(Registrant)

Date:  November 10, 2008

/s/Andrew Makrides

Chief Executive Officer - Andrew Makrides

/s/Gary D. Pickett

Chief Financial Officer- Gary D. Pickett

24